Bor türevlerinin meme kanseri hücrelerinin çoğalması ve tümöre özgü T hücreleri üzerindeki etkilerinin in vitro olarak farklı mekanizmalarla incelenmesi

Breast cancer is the most commonly identified cancer in women throughout the world. Despite the initial clinical response obtained with the widely used conventional chemotherapy, an improved prognosis for breast cancer individuals has been missing in the clinic because of the high toxicity to normal cells, induction of drug resistance, and the potential immunosuppressive effects of these agents. Therefore, our objective was to examine the potential anti-proliferative ability of some boron derivatives (SPP) and (SPT), which showed a promising effect on some types of cancers in the literature, on breast cancer cell lines as well as immuno-oncological side effects on tumor-specific T cell activity. These findings suggest that both SPP and SPT suppressed proliferation and induced apoptosis in MCF-7 and MDA-MB231 cancer cell lines through downregulation of the monopolar spindle-one-binder (MOB1) protein. Contrarily, these molecules increased the expression of CD274 protein through their effect on the phosphorylation level of Yes-associated protein. In addition, they reduced the concentrations of pro-inflammatory cytokines such as IFN-γ and cytolytic effector cytokines such as sFasL, perforin, granzyme A, Granzyme B, and granulysin and raised the level of CD279 surface protein in activated T cells. In conclusion, SPP, SPT, and their combination could have growth inhibitory (antiproliferative) effects and could be a therapeutic option for breast cancer. However, their stimulatory effects on the PD-1/PD-L1 signaling pathway and their effects on cytokines could ultimately account for the observed repression of the charging of effector T cells that have been particularly activated against breast cancer cells. This study paved the way for a future line of research to investigate the anti-carcinogenic effect of the boron derivatives in vivo and the synergistic effect of these boron derivatives with an optimal dose and modified T cells activated against breast cancer cells.